Drug Trial Radar · NCT01290939
Bevacizumab and Lomustine for Recurrent GBM
Last checked: Nov 20, 2026Latest source record: Feb 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
592
Actual
Start
Oct 2011
Primary completion
Oct 2015
Study completion Apr 2020
Sponsor
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTCResearch network
- Sponsor type
- Research network
- Collaborators
- Hoffmann-La Roche
- First posted
- Feb 7, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which regimen of bevacizumab given together with lomustine is most effective in treating patients with glioblastoma multiforme in first recurrence. PURPOSE: The primary objective of this study is to investigate whether the addition of bevacizumab to lomustine improves overall survival (OS) in patients with recurrent glioblastoma compared to treatment with lomustine alone.
Conditions
- Glioblastoma Multiforme
- Cognition Disorders
- Disability Evaluation
Interventions
bevacizumabBiological
lomustineDrug
DNA methylation analysisGenetic
laboratory biomarker analysisOther
cognitive assessmentProcedure
quality-of-life assessmentProcedure
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: Time to event
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Erasmus MC - Daniel den Hoed Cancer Center
Rotterdam, Netherlands
Medisch Centrum Haaglanden - Westeinde
The Hague, Netherlands
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.